Saad Usmani, MD, MBBS, MBA, Levine Cancer Institute, Charlotte, NC, shares details of the upcoming KarMMa-4 Phase I study (NCT04196491) of idecabtagene vicleucel (ide-cel, bb2121), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, in high-risk newly diagnosed multiple myeloma. High-risk patients that are enrolled in to this multicenter, open-label trial will initially be treated with induction therapy followed by ide-cel infusion at a starting target dose of 450 x 10^6 CAR+ T cells, with dose escalation/de-escalation. Following identification of the optimal target dose, further patients will be enrolled for the dose-expansion phase. It is hoped that trials such as this will support the initiation of future studies into the use of CAR-T therapies in the newly diagnosed setting for high-risk myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.